Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches
Authors:
- Ayesha KhanAKAyesha Khan
- Arsal KhanAKArsal Khan
- Kuldeep Dalpat RaiKRKuldeep Dalpat Rai
- Anzel SaeedASAnzel Saeed
- Harsh KumarHKHarsh Kumar
- Aneesh Kumar SangtianiASAneesh Kumar Sangtiani
- Tehreem FatimaTFTehreem Fatima
- Faiza RajputFRFaiza Rajput
- Hussain Haider ShahHSHussain Haider Shah
- Humaira KalamHKHumaira Kalam
Open Access
- 29 April 2026
- journal article
- review article
- Published by Wiley in Brain and Behavior
- Vol. 16 (5) , e71458
Abstract
Purpose of Review : This review aims to provide a comprehensive analysis of chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on its clinical manifestations, pathophysiology, and treatment advancements, with particular emphasis on efgartigimod as a novel therapeutic agent. Recent Findings : CIDP is a chronic autoimmune disorder caused by demyelination and axonal degeneration, leading to progressive weakness and impaired sensory function. While conventional treatments, including corticosteroids, IVIg, and plasma exchange, provide symptomatic relief, their limitations include significant side effects and resistance in some cases. Efgartigimod, an FcRn blocker targeting the IgG catabolic pathway, has emerged as a promising therapy. The ADHERE study demonstrated a 61% reduction in CIDP relapses with efgartigimod, alongside improved disability scores and a favorable safety profile. Summary : CIDP presents significant diagnostic and therapeutic challenges, requiring tailored approaches to management. Efgartigimod introduces a targeted mechanism of action, offering hope for patients unresponsive to traditional therapies. Further research is needed to establish its long‐term efficacy and optimal role in CIDP treatment strategies.Keywords
This publication has 173 references indexed in Scilit:
- Magnetic resonance imaging at the demyelinative foci in chronic inflammatory demyelinating polyneuropathyNeurology, 1997
- Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositisJournal of Neuroimmunology, 1996
- Inflammatory infiltrates in sural nerve biopsies in Guillain-Barr syndrome and chronic inflammatory demyelinating neuropathyMuscle & Nerve, 1996
- Expression of endothelial leukocyte adhesion molecule‐1 (ELAM‐1) in chronic inflammatory demyelinating polyneuropathyNeurology, 1994
- Increased serum levels of ICAM-1, ELAM-1 and TNF-α in inflammatory disorders of the peripheral nervous systemThe Italian Journal of Neurological Sciences, 1994
- Serum interleukin‐2 concentrations in Guillain‐Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: Comparison with other neurological diseases of presumed immunopathogenesisAnnals of Neurology, 1991
- Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathyJournal of Neuroimmunology, 1986
- Plasma Exchange in Chronic Inflammatory Demyelinating PolyradiculoneuropathyNew England Journal of Medicine, 1986
- Immunoglobulin and Complement Deposits in Nerves of Patients With Chronic Relapsing PolyneuropathyArchives of Neurology, 1980
- Chronic relapsing polyneuritisJournal of the Neurological Sciences, 1976